RVL Pharmaceuticals PLC Investor Relations Material
Latest events
Q2 2023
RVL Pharmaceuticals PLC
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from RVL Pharmaceuticals PLC
Access all reports
RVL Pharmaceuticals PLC is a specialty pharmaceutical company that focuses on developing and commercializing products in the ocular and medical aesthetics sectors. Its main product, Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%), is FDA-approved for the treatment of acquired blepharoptosis, or low-lying eyelids, offering a non-surgical option for adults. The company serves underserved patient populations primarily in the United States and operates in several international markets. RVL Pharmaceuticals is headquartered in Bridgewater, New Jersey, and its shares are listed on the OTC Markets.
Latest articles
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
RVLP
Country
πΊπΈ United States